Peptide manufacturers should take care to avoid regulatory trap

- Last updated on GMT

Manufacturers of new generation peptides need to tread finely with their marketing claims to avoid being classified as a medicine, says HelixBioMedix's Robin Carmichael.

Manufacturers of new generation peptides need to tread finely with their marketing claims to avoid being classified as a medicine, says HelixBioMedix's Robin Carmichael.

Related topics: Formulation & Science

Related news

Follow us

Products

View more

Webinars